Trials / Completed
CompletedNCT01098084
Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML)
A Phase II Study of Decitabine in Patients With Chronic Myelomonocytic Leukemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Groupe Francophone des Myelodysplasies · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to determine the therapeutic efficacy of Decitabine in patients with chronic myelomonocytic leukemia (CMML) diagnosis according to WHO criteria either untreated or previously treated with Hydrea or Etoposide (given orally), non intensive chemotherapy or intensive chemotherapy given more than 3 months before inclusion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Decitabine | 20mg/m2/day, one hour intravenous infusion, every day during 5 days |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2009-06-01
- Completion
- 2009-06-01
- First posted
- 2010-04-02
- Last updated
- 2014-03-20
Locations
31 sites across 1 country: France
Source: ClinicalTrials.gov record NCT01098084. Inclusion in this directory is not an endorsement.